These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort. Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN; J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685 [TBL] [Abstract][Full Text] [Related]
3. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hosaka T; Suzuki F; Kobayashi M; Seko Y; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H Hepatology; 2013 Jul; 58(1):98-107. PubMed ID: 23213040 [TBL] [Abstract][Full Text] [Related]
4. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK; Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118 [TBL] [Abstract][Full Text] [Related]
5. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799 [TBL] [Abstract][Full Text] [Related]
7. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy. Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649 [TBL] [Abstract][Full Text] [Related]
8. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450 [TBL] [Abstract][Full Text] [Related]
9. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B. Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267 [TBL] [Abstract][Full Text] [Related]
10. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH; Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134 [TBL] [Abstract][Full Text] [Related]
11. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Chang TT; Lai CL; Kew Yoon S; Lee SS; Coelho HS; Carrilho FJ; Poordad F; Halota W; Horsmans Y; Tsai N; Zhang H; Tenney DJ; Tamez R; Iloeje U Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753 [TBL] [Abstract][Full Text] [Related]
12. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800 [TBL] [Abstract][Full Text] [Related]
13. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting. Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108 [TBL] [Abstract][Full Text] [Related]
14. Rescue monotherapy in lamivudine-resistant hepatitis B e antigen-positive chronic hepatitis B: adefovir versus entecavir. Lee JM; Kim HJ; Park JY; Lee CK; Kim DY; Kim JK; Lee HW; Paik YH; Lee KS; Han KH; Chon CY; Hong SP; Nguyen T; Ahn SH Antivir Ther; 2009; 14(5):705-12. PubMed ID: 19704174 [TBL] [Abstract][Full Text] [Related]
15. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. Ren FY; Piao DM; Piao XX World J Gastroenterol; 2007 Aug; 13(31):4264-7. PubMed ID: 17696259 [TBL] [Abstract][Full Text] [Related]
16. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Cho JY; Paik YH; Sohn W; Cho HC; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Gut; 2014 Dec; 63(12):1943-50. PubMed ID: 24615378 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288 [TBL] [Abstract][Full Text] [Related]
18. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong. Lee KK; Wu DB; Chow PY; Lee VW; Li H J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402 [TBL] [Abstract][Full Text] [Related]
19. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis. Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701 [TBL] [Abstract][Full Text] [Related]
20. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma. Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]